• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Design Therapeutics Inc.

    3/10/25 7:30:27 AM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DSGN alert in real time by email
    S-8 1 dsgn-20250310.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on March 10, 2025

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    Design Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware

    82-3929248

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

     

     

    6005 Hidden Valley Road, Suite 110

    Carlsbad, California

    92011

    (Address of Principal Executive Offices)

    (Zip Code)

     

     

    2021 Equity Incentive Plan

    2021 Employee Stock Purchase Plan

    (Full titles of the plans)

    Pratik Shah, Ph.D.

    President, Chief Executive Officer and Chairperson

    Design Therapeutics, Inc.

    6005 Hidden Valley Road, Suite 110

    Carlsbad, California 92011

    (858) 293-4900

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

    Kenneth J. Rollins, Esq.

    Asa M. Henin, Esq.

    Cooley LLP

    10265 Science Center Drive

    San Diego, California 92121

    (858) 550-6000

     

     

     


     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☐

    Accelerated Filer

    ☐

    Non-accelerated filer

    

    Smaller reporting company

    

     

     

     Emerging growth company

    

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. 

     

     


     

    REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E

     

    This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which Registration Statements of the Registrant on Form S-8 relating to the same employee benefit plans are effective.

     

    The Registrant previously registered shares of Common Stock for issuance under its 2021 Equity Incentive Plan and its 2021 Employee Stock Purchase Plan under Registration Statements on Form S-8, filed with the Securities and Exchange Commission on March 26, 2021 (File No. 333-254794), March 10, 2022 (File No. 333-263427), March 14, 2023 (File No. 333-270527) and March 19, 2024 (File No. 333-278064). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.

     

    PART II

     

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.

     

    The following documents filed by the registrant with the Securities and Exchange Commission (SEC) are incorporated by reference into this registration statement:

     

    •
    the Registrant's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 10, 2025; and
    •
    the description of the registrant's common stock contained in the registrant's registration statement on Form 8-A, filed with the SEC on March 23, 2021, including any amendments or reports filed for the purpose of updating such description, including Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023.

     

    All reports and other documents filed by the registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, other than Current Reports furnished under Item 2.02 or Item 7.01 of exhibits furnished on such form that relate to such items and other portions of documents that are furnished but not filed or are otherwise not incorporated into registration statements pursuant to the applicable rules promulgated by the SEC, after the date of this registration statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this registration statement from the date of filing such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes that statement. Any such statement so modified or superseded shall not constitute a part of this registration statement, except as so modified or superseded.

     

    ITEM 8.

    EXHIBITS.

     

     

     

    Exhibit
    Number

    Description

     

     

    4.1

    Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of Registrant’s Current Report on Form 8-K, filed with the SEC on March 30, 2021).

     

     

    4.2

    Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 of Registrant’s Current Report on Form 8-K, filed with the SEC on March 30, 2021).

     

     

    4.3

    Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-253954), filed with the SEC on March 22, 2021).

     

     

    5.1

    Opinion of Cooley LLP.

     

     

    23.1

    Consent of Independent Registered Public Accounting Firm.

     

     

    23.2

    Consent of Cooley LLP. Reference is made to Exhibit 5.1.

     

     

     


     

    24.1

    Power of Attorney. Reference is made to the signature page hereto.

     

     

    99.1

    Design Therapeutics, Inc. 2021 Equity Incentive Plan, and Forms of Option Grant Notice, Option Agreement and Notice of Exercise thereunder (incorporated by reference to Exhibit 10.3 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-253954), filed with the SEC on March 22, 2021).

     

     

    99.2

    Design Therapeutics, Inc. 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.4 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-253954), filed with the SEC on March 22, 2021).

     

     

     

     

    107

     

    Filing Fee Table.

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Carlsbad, State of California, on March 10, 2025.

     

     

     

    DESIGN THERAPEUTICS, INC.

     

     

    By:

    /s/Pratik Shah, Ph.D.

     

    Pratik Shah, Ph.D.

     

    President, Chief Executive Officer and Chairperson

     

     


     

    POWER OF ATTORNEY

     

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Pratik Shah, Ph.D., as his or her true and lawful attorney-in-fact and agent with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

     

     

     

     

     

    Signature

    Title

    Date

     

     

     

    /s/ Pratik Shah, Ph.D.

    Pratik Shah, Ph.D.

    President, Chief Executive Officer and Chairperson

    (Principal Executive and Financial Officer)
     

    March 10, 2025

     

     

     

    /s/ Julie Burgess

    Julie Burgess

    Chief Accounting Officer
    (Principal Accounting Officer)

    March 10, 2025

     

     

     

    /s/ Simeon George, M.D.

    Simeon George, M.D.

    Director

    March 10, 2025

     

     

     

    /s/ Rodney Lappe, Ph.D.

    Rodney Lappe, Ph.D.

    Director

    March 10, 2025

     

     

     

    /s/ John Schmid

    John Schmid

    Director

    March 10, 2025

     

     

     

    /s/ Arsani William, M.D.

    Arsani William, M.D.

    Director

    March 10, 2025

    /s/ Heather Berger, Ph.D.

    Director

    March 10, 2025

    Heather Berger, Ph.D.

     

    /s/ Deepa Prasad

    Director

    March 10, 2025

    Deepa Prasad

     

     


    Get the next $DSGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DSGN

    DatePrice TargetRatingAnalyst
    5/7/2024$6.00 → $12.00Neutral → Overweight
    Piper Sandler
    11/14/2023$42.00 → $6.00Overweight → Neutral
    Piper Sandler
    8/15/2023$19.00 → $6.00Outperform → Neutral
    Wedbush
    8/15/2023$23.00 → $7.00Outperform → Sector Perform
    RBC Capital Mkts
    8/15/2023$6.00Outperform → Market Perform
    SVB Securities
    5/4/2023$6.00Sell → Neutral
    Goldman
    6/10/2022$21.00Outperform
    Wedbush
    5/2/2022$30.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $DSGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Schmid John P. bought $99,738 worth of shares (26,965 units at $3.70) (SEC Form 4)

      4 - Design Therapeutics, Inc. (0001807120) (Issuer)

      3/25/24 7:10:26 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berger Heather A. bought $4,866 worth of shares (1,300 units at $3.74) (SEC Form 4)

      4 - Design Therapeutics, Inc. (0001807120) (Issuer)

      3/25/24 7:09:14 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lappe Rodney W bought $49,287 worth of shares (21,000 units at $2.35), increasing direct ownership by 19% to 133,024 units (SEC Form 4)

      4 - Design Therapeutics, Inc. (0001807120) (Issuer)

      10/2/23 6:01:58 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DSGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Dunham Trust Co

      3 - Design Therapeutics, Inc. (0001807120) (Issuer)

      2/7/25 4:17:28 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Lappe Rodney W

      4 - Design Therapeutics, Inc. (0001807120) (Issuer)

      1/6/25 7:00:35 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President, CEO and Chairperson Shah Pratik

      4 - Design Therapeutics, Inc. (0001807120) (Issuer)

      1/6/25 7:00:31 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DSGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Design Therapeutics Inc.

      SC 13D/A - Design Therapeutics, Inc. (0001807120) (Subject)

      8/13/24 6:53:06 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Design Therapeutics Inc. (Amendment)

      SC 13G/A - Design Therapeutics, Inc. (0001807120) (Subject)

      2/14/24 4:58:16 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Design Therapeutics Inc. (Amendment)

      SC 13G/A - Design Therapeutics, Inc. (0001807120) (Subject)

      2/14/24 3:01:26 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DSGN
    Financials

    Live finance-specific insights

    See more
    • Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

      New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025 IND Cleared for DT-168 for Treatment of Fuchs Endothelial Corneal Dystrophy (FECD) with Phase 1 Development to Start in 2024; Observational Study Underway to Confirm Patient Characteristics and Evaluate Potential Endpoints New Program Unveiled for Huntington's Disease (HD) Targeting Reduction of Mutant Huntingtin with a GeneTAC™ Small Molecule Cash and Securities of $281.8 Million at Year-end 2023 Support Five-Year Operating Runway and Advancement of Up to Four Progra

      3/19/24 4:01:00 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

      CARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 19, 2024, at 4:30 p.m. ET to discuss its fourth quarter and full year 2023 financial results and provide a comprehensive portfolio update. The event will be webcast live under the "Events" section of the Investors page of www.designtx.com and can also be accessed here. A replay of the webcast will be archived on the Design website for 30 days. Dial-in information for conference participants may be obtained by regi

      3/12/24 6:30:00 AM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia

      DT-216 Resulted in a Significant Increase in FXN mRNA Levels in Skeletal Muscle of FA Patients Treatment Generally Well-Tolerated; Injection Site Reactions Attributable to Current Formulation Composition Design Plans to Proceed with an Improved DT-216 Formulation and Initiate a Multiple Dose Phase 1 Clinical Study in the Second Half of 2024 Conference Call and Webcast to be Held Today at 4:30pm ET CARLSBAD, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported initial results from the company's Phase 1 multiple-ascending dose (MAD) clinical

      8/14/23 4:01:00 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DSGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer

      CARLSBAD, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of Chris M. Storgard, M.D., as Chief Medical Officer (CMO). Dr. Storgard brings over two decades of leadership and hands-on drug development experience, having successfully advanced multiple assets from preclinical stages through global regulatory approvals. "We are thrilled to welcome Chris to our team at this exciting time for Design, as we advance our portfolio of GeneTAC® small molecules toward key clinical milestones," said Pratik Shah, Ph.D., chairperson an

      4/17/25 8:00:00 AM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services
    • Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results

      Phase 1 Trial of DT-216, a Novel FA GeneTAC™ Molecule, in Patients with Friedreich Ataxia On Track to Begin Soon Preclinical Data Supporting Development of Novel GeneTAC™ Small Molecules for the Treatment of Fuchs Endothelial Corneal Dystrophy (FECD) to be Presented at ARVO 2022 Well-Capitalized with $384.1 Million in Cash and Investments at the End of 2021 to Support Upcoming Milestones CARLSBAD, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced pipeline and business progress and reported fourth quarter and full year 2021 financial results. "This is an e

      3/10/22 4:02:00 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DSGN
    SEC Filings

    See more
    • SEC Form S-3 filed by Design Therapeutics Inc.

      S-3 - Design Therapeutics, Inc. (0001807120) (Filer)

      5/7/25 4:54:16 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Design Therapeutics Inc.

      10-Q - Design Therapeutics, Inc. (0001807120) (Filer)

      5/7/25 4:07:23 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Design Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Design Therapeutics, Inc. (0001807120) (Filer)

      5/7/25 4:04:40 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DSGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Design Therapeutics upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Design Therapeutics from Neutral to Overweight and set a new price target of $12.00 from $6.00 previously

      5/7/24 6:22:26 AM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Design Therapeutics downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Design Therapeutics from Overweight to Neutral and set a new price target of $6.00 from $42.00 previously

      11/14/23 11:39:53 AM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Design Therapeutics downgraded by Wedbush with a new price target

      Wedbush downgraded Design Therapeutics from Outperform to Neutral and set a new price target of $6.00 from $19.00 previously

      8/15/23 7:30:45 AM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DSGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results

      Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) Program Well-Capitalized with Cash and Securities of $229.7 Million to Fund Operations Through up to Four Potential Clinical Proof-of-Concept Data Sets CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced progress across its portfolio of GeneTAC® candidates and reported financial results for the first quarter 2025. "Design continued its progress throug

      5/7/25 4:01:00 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

      CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced favorable data from a Phase 1 single- and multiple-ascending dose (SAD/MAD) trial of DT-168 in healthy volunteers, which will be presented on May 2, 2025 at Eyecelerator @ Park City 2025, an event backed by the American Academy of Ophthalmology highlighting industry advancements and innovative new products disrupting eye care. DT-168 is a novel GeneTAC® small molecule, formulated as an eye drop, that is designed to selectively target and reduce the expression of the mutant TCF4 ge

      5/1/25 8:00:00 AM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

      CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that it will present an update on the progress of its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) at Eyecelerator @ Park City 2025 on Friday, May 2, 2025, at 1:30 p.m. MT in Park City, UT. The presentation will include safety findings from the Phase 1 single- and multiple-ascending dose trial of DT-168 in healthy adult volunteers and plans for Phase 2 clinical development in FECD patients. DT-168 is a GeneTAC® small molecule, formulated as an eye drop, that is

      4/21/25 4:01:00 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care